Velesco expands core scientific and quality team

Appoints director of quality and senior pharmaceutical scientist

Contract research organisation Velesco Pharmaceutical Services, which operates from facilities in Plymouth and Kalamazoo, Michigan, US, has added Shirley Smith as director of quality and Yuan Chen as senior pharmaceutical scientist.

Prior to joining Velesco, Smith was quality assurance manager for Richard-Allan Scientific and senior quality assurance manager for Pfizer’s Drug Product and Device Research Group in Kalamazoo, MI.

In conjunction with her role at Velesco, Smith will continue her leadership position at PharmaMed Resources, a quality assurance and regulatory affairs consultancy that services the Medical Device and Pharmaceutical Industries.

Chen has extensive experience in analytical methods development and validation, cleaning verification and validation, and drug release testing.

Before joining Velesco, Chen served in the Pharmaceutical Sciences Division of Pfizer Global R&D as a senior associate scientist for eight years and the Analytical Development Department of Caraco Pharmaceutical Laboratories for two years. Her experience spans the drug development spectrum from early stage development and validation of stability-indicating methods for the release of drug substance and drug product, to later stage projects focused on the detection of residual drugs on manufacturing equipment.

You may also like

Research & Development

Velesco Pharma expands and opens new cGMP-compliant analytical testing laboratory

Increases the breadth of its services to meet client needs
Regulatory

TurboFil debuts latest generation of through-the-tip benchtop syringe filler

TipFil Plus provides precise, aseptic-ready filling and capping for lab and pharmacy applications
Manufacturing

Concentrating recombinant proteins for drug discovery using centrifugal evaporation

Exploring purification, concentration and sample protection in recombinant protein workflows
Research & Development

COVID-19 immunity lowers the risk of a new pandemic

Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Cytiva enters research partnership with SRTIGET for next-gen genomic medicine

The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens
Research & Development

Shimadzu’s Design Craftech

Fusing traditional Kyoto craft techniques with industrial production
Research & Development

Just – Evotec Biologics wins BARDA contract to optimise antibody biomanufacturing against Ebola and Sudan virus

Just – Evotec Biologics has been selected by BARDA to develop scalable, high-yield manufacturing processes for a monoclonal antibody cocktail targeting filovirus diseases under a multi-year programme valued at up to $10m
Subscribe now